Gilead's Trodelvy stumbles in first-line breast cancer trial, adding to shaky clinical track record
7th November 2025 Uncategorised 0Gilead revealed that Trodelvy has come up short as a first-line treatment for patients with HR+/HER2-negative metastatic breast cancer. The company said that the phase 3 Ascent-07 study comparing Trodelvy to chemotherapy failed to meet its primary endpoint of progression-free survival.
More: Gilead's Trodelvy stumbles in first-line breast cancer trial, adding to shaky clinical track record
Source: fierce